In this study, we demonstrate that leriglitazone can stop neuroinflammation and halt disease progression in most men with cerebral adrenoleukodystrophy.
Adrenoleukodystrophy: Leriglitazone Halts Early Cerebral Forms
Event
4 June 2024
